Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avalo Therapeutics, Inc.
Report date December 01, 2021 · Filed December 04, 2021
Section 16 reporting ended · disclosed 2021-12-04. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
LENZ Therapeutics, Inc.
Report date April 11, 2022 · Filed April 13, 2022
Section 16 reporting ended · disclosed 2022-04-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 299,941 |
Reported balance
After 2022-04-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-11 · Purchase · Acquired 5,000 · Balance 299,941 F1: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 11, 2022 Filed Apr 13, 2022 23:35 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | PurchaseCommon Stock | 5,000 | $4.01 | $20,050.00 |
DisclosureSEC source: 0001209191-22-024362 · doc4.xml · nonDerivative · entry 1 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,941 F1 · balance_after: Includes 1,470 shares acquired under the Graphite Bio, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:56 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-22-011465 · doc4.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:45 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,718 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001878894-21-000011 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,718 Underlying: Common Stock · 4,718 shares Expires 2031-09-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:06 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,142 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001192482-21-000600 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,142 Underlying: Common Stock · 3,142 shares Expires 2031-06-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Preferred Stock · Derivative | 19,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 10 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 8,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 3 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:41 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001192482-21-000524 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-15 F1 · shares: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 18, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionStock Option (right to buy) · Derivative | 3,383 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 9 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,027 Underlying: Common Stock · 3,383 shares Expires 2031-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| April 18, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionCommon Stock | 3,383 | $6.11 | $20,670.13 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 2 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:25 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,783 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001653224-21-000001 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,783 Underlying: Common Stock · 3,783 shares Expires 2031-03-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| March 17, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 69,604 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 8 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,604 Underlying: Common Stock · 69,604 shares Expires 2031-03-16 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F6 · derivative.exercise_date: The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 17, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 162,410 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 7 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,410 Underlying: Common Stock · 162,410 shares Expires 2031-03-16 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 11, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantSeries B Preferred Stock · Derivative | 19,763 | $5.06 | $100,000.78 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 6 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,763 Underlying: Common Stock · 8,126 shares Expires not disclosed F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| January 15, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionStock Option (right to buy) · Derivative | 91,406 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 5 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,406 shares Expires 2031-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| January 15, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | Exercise / conversionCommon Stock | 91,406 | $0.30 | $27,421.80 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · nonDerivative · entry 1 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| January 13, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 91,406 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-21-027016 · doc4.xml · derivative · entry 4 Gutry Phil · CIK 0001653224 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,406 Underlying: Common Stock · 91,406 shares Expires 2031-01-12 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 5, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:17 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,877 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001192482-21-000032 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,877 Underlying: Common Stock · 3,877 shares Expires 2030-12-31 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:43 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,516 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001192482-20-000759 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,516 Underlying: Common Stock · 4,516 shares Expires 2030-09-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:49 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,812 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001192482-20-000595 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,812 Underlying: Common Stock · 3,812 shares Expires 2030-06-30 F1 · shares: 100% of this stock option will immediately vest on the date that it is granted. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:11 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000544 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-18 F1 · shares: This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:49 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 4,310 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001578563-20-000008 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2030-03-31 F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:56 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 2,375 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001578563-20-000001 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,375 Underlying: Common Stock · 2,375 shares Expires 2029-12-31 F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:30 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,907 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001578563-19-000026 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,907 Underlying: Common Stock · 3,907 shares Expires 2029-09-30 F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 07, 2019 Filed Oct 3, 2019 21:20 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001578563-19-000030 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-08-07 F1 · derivative.exercise_date: The stock option will vest in full on August 7, 2020, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:08 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 2,323 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001104659-19-039024 · a4.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,323 Underlying: Common Stock · 2,323 shares Expires 2029-06-28 Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 19:39 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,916 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001562180-19-002071 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 Underlying: Common Stock · 1,916 shares Expires 2029-03-29 Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:29 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 3,439 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001578563-19-000002 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,439 Underlying: Common Stock · 3,439 shares Expires 2028-12-30 Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 18:16 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,351 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001562180-18-004061 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,351 Underlying: Common Stock · 2,351 shares Expires 2028-09-28 Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 21:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,544 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001562180-18-003173 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544 Underlying: Common Stock · 2,544 shares Expires 2028-06-29 Read SEC document |
| May 15, 2018 Filed May 17, 2018 23:34 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 8,357 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001578563-18-000008 · primary_doc.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,357 Underlying: Common Stock · 8,357 shares Expires 2028-05-14 F1 · derivative.exercise_date: The stock options will vest in full on May 15, 2019, subject to the grantee's continued service on such vesting date. Read SEC document |
| March 31, 2018 Filed Apr 4, 2018 18:36 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,350 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001562180-18-001830 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,350 Underlying: Common Stock · 2,350 shares Expires 2028-03-30 Read SEC document |
| December 31, 2017 Filed Jan 4, 2018 15:21 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,179 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001562180-18-000179 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,179 Underlying: Common Stock · 3,179 shares Expires 2027-12-30 Read SEC document |
| September 30, 2017 Filed Oct 4, 2017 18:24 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,600 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-17-003189 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2027-09-29 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 17:40 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,224 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001562180-17-002386 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,224 Underlying: Common Stock · 14,224 shares Expires 2027-06-29 F1 · derivative.exercise_date: The stock options vested immediately and became exercisable in full upon grant on 6/30/2017. Read SEC document |
| June 30, 2017 Filed Jul 31, 2017 17:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,357 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001562180-17-002533 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,357 Underlying: Common Stock · 8,357 shares Expires 2027-06-29 F1 · derivative.exercise_date: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 18:17 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,131 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001562180-17-001405 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,131 Underlying: Common Stock · 10,131 shares Expires 2027-03-30 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 19:55 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,793 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001562180-17-000141 · primarydocument.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,793 Underlying: Common Stock · 3,793 shares Expires 2026-12-30 F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on December 31, 2016. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 19:11 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 886 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001179110-16-030161 · edgar.xml · derivative · entry 1 Gutry Phil · CIK 0001653224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886 Underlying: Common Stock · 886 shares Expires 2026-09-29 F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on September 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.